Target Name: TIPRL
NCBI ID: G261726
Review Report on TIPRL Target / Biomarker Content of Review Report on TIPRL Target / Biomarker
TIPRL
Other Name(s): TIPRL1 | TIPRL variant 1 | CG9578-like | TIP41, TOR signaling pathway regulator-like | TIP41-like protein | Putative MAPK activating protein | TIP41, TOR signalling pathway regulator-like | TIP41-like protein (isoform 1) | Type 2A-interacting protein | dJ69E11.3 | TOR signaling pathway regulator, transcript variant 1 | RP1-69E11.1 | TIP41 | Putative MAPK-activating protein PM10 | putative MAPK-activating protein PM10 | MGC3794 | Yeast YPR037W and worm C02C2.6 predicted proteins-like | TIP | type 2A-interacting protein | TOR signaling pathway regulator | TIPRL_HUMAN

TIPRL1: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of current pain treatments has led to a growing interest in developing new and innovative approaches to treat chronic pain. TIPRL1, a novel protein that has recently been identified as a potential drug target and biomarker for the treatment of chronic pain, is a promising target for future pain management strategies. This article will provide an overview of TIPRL1, its potential as a drug target and biomarker, and the current research efforts to investigate its potential in the treatment of chronic pain.

Introduction:
Chronic pain is a persistent and often debilitating condition that can have significant impacts on an individual's quality of life. The World Health Organization (WHO) estimates that chronic pain affects approximately 12% of the global population, with costs associated with chronic pain reaching $600 billion annually. While there are currently a variety of treatments available for chronic pain, many of these treatments are limited in their effectiveness and can have potential side effects. The search for new and innovative approaches to treat chronic pain has led to the development of TIPRL1, a protein that has shown promise as a potential drug target and biomarker for the treatment of chronic pain.

TIPRL1: A novel protein and its potential as a drug target:
TIPRL1 is a protein that is expressed in various tissues and cells throughout the body, including the brain, spinal cord, and peripheral tissues. It is characterized by a unique N-terminus that consists of a conserved domain and a unique amino acid sequence. The The conserved domain of TIPRL1 is composed of a unique alpha-helix that is similar to other proteins that are involved in the regulation of pain signaling. The unique amino acid sequence of the N-terminus of TIPRL1 is known as the \"pain associated protein\ " (PAP) domain and is thought to be involved in the regulation of pain signaling.

Recent studies have shown that TIPRL1 is involved in the regulation of pain signaling in various organisms, including mammals. For example, TIPRL1 has been shown to play a role in the regulation of pain signaling in the central nervous system (CNS) and is involved in the modulation of pain sensitivity. Additionally, TIPRL1 has been shown to be involved in the regulation of pain signaling in peripheral tissues, such as muscles and bones.

TIPRL1 has also been shown to be a potential drug target for the treatment of chronic pain. The failure of current pain treatments has led to a growing interest in developing new and innovative approaches to treat chronic pain. TIPRL1 is a potential target for pain management strategies because of its involvement in the regulation of pain signaling and its unique amino acid sequence.

TIPRL1 as a biomarker:
In addition to its potential as a drug target, TIPRL1 has also been shown to be a potential biomarker for the treatment of chronic pain. The failure of current pain treatments has led to a growing interest in developing new approaches to diagnose and treat chronic pain. TIPRL1 has been shown to be expressed in various tissues and cells throughout the body and its levels have been shown to be affected by various factors, including pain signaling. This suggests that TIPRL1 could be used as a biomarker for the diagnosis and treatment of chronic pain.

Current research efforts:
The search for new and innovative approaches to treat chronic pain has led to the development of TIPRL1 as a potential drug target and biomarker. Current research efforts are focused on investigating the role of TIPRL1 in the regulation of pain signaling and its potential as a drug target and biomarker for the treatment of chronic pain.

Conclusion:
TIPRL1 is a novel protein that has shown promise as a potential drug target and biomarker for the treatment of chronic pain. Its unique amino acid sequence and its involvement in the regulation of pain signaling make it a promising target for future pain management strategies. Further research is needed to

Protein Name: TOR Signaling Pathway Regulator

Functions: May be a allosteric regulator of serine/threonine-protein phosphatase 2A (PP2A). Isoform 1 inhibits catalytic activity of the PP2A(D) core complex in vitro. The PP2A(C):TIPRL complex does not show phosphatase activity. Acts as negative regulator of serine/threonine-protein phosphatase 4 probably by inhibiting the formation of the active PPP4C:PPP4R2 complex; the function is proposed to implicate it in DNA damage response by promoting H2AX phosphorylated on Ser-140 (gamma-H2AX). May play a role in the regulation of ATM/ATR signaling pathway controlling DNA replication and repair

The "TIPRL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIPRL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TIRAP | TIRAP-AS1 | TJAP1 | TJP1 | TJP2 | TJP3 | TK1 | TK2 | TKFC | TKT | TKTL1 | TKTL2 | TLCD1 | TLCD2 | TLCD3A | TLCD3B | TLCD4 | TLCD4-RWDD3 | TLCD5 | TLDC2 | TLE1 | TLE1-DT | TLE2 | TLE3 | TLE4 | TLE5 | TLE6 | TLK1 | TLK2 | TLL1 | TLL2 | TLN1 | TLN2 | TLNRD1 | TLR1 | TLR10 | TLR12P | TLR2 | TLR3 | TLR4 | TLR5 | TLR6 | TLR7 | TLR8 | TLR8-AS1 | TLR9 | TLX1 | TLX1NB | TLX2 | TLX3 | TM2D1 | TM2D2 | TM2D3 | TM4SF1 | TM4SF1-AS1 | TM4SF18 | TM4SF19 | TM4SF19-AS1 | TM4SF19-DYNLT2B | TM4SF20 | TM4SF4 | TM4SF5 | TM6SF1 | TM6SF2 | TM7SF2 | TM7SF3 | TM9SF1 | TM9SF2 | TM9SF3 | TM9SF4 | TMA16 | TMA7 | TMBIM1 | TMBIM4 | TMBIM6 | TMC1 | TMC2 | TMC3 | TMC4 | TMC5 | TMC6 | TMC7 | TMC8 | TMCC1 | TMCC1-DT | TMCC2 | TMCC3 | TMCO1 | TMCO1-AS1 | TMCO2 | TMCO3 | TMCO4 | TMCO5A | TMCO5B | TMCO6 | TMED1 | TMED10 | TMED10P1 | TMED11P | TMED2